Portola's Supplementary Approval Paves Way For Belated Bevyxxa Launch
Bevyxxa finally set to become the fifth new oral anticoagulant on the US market, but in a unique, niche indication of acute medical illness.
Bevyxxa finally set to become the fifth new oral anticoagulant on the US market, but in a unique, niche indication of acute medical illness.